drugset / Trial / NCT00279747

A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

NCT00279747

Phase 3 Completed 226 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.

Timeline

Start
2000-09
Primary completion
2003-01
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 0.125 mg/kg Oral
Subject Meloxicam Small molecule 0.25 mg/kg Oral
Subject Naproxen Small molecule 10 mg/kg Oral